Switzerland· 67596005
Enerzair Breezhaler Inha
A indacaterol, glycopyrronium bromid und mometason product containing indacaterolum, glycopyrronium, mometasoni furoas, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Indacaterol, glycopyrronium bromid und mometason is registered in 11 of 19 countries.
Countries holding a registration under ATC R03AL12 (indacaterol, glycopyrronium bromid und mometason), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Indacaterol, glycopyrronium bromid und mometason · ATC R03AL12
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- indacaterolum, glycopyrronium, mometasoni furoas
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- R03AL12
- ATC class
- Indacaterol, Glycopyrronium bromid und Mometason
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680675960057Blist 90 StkCHF 194.5
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Indacaterol, glycopyrronium bromid und mometason in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainENERZAIR BREEZHALER 114 MICROGRAMOS/46 MICROGRAMOS/136 MICROGRAMOS POLVO PARA INHALACION (CAPSULA DURA)Novartis Europharm Limited
- IcelandEnerzair BreezhalerNovartis Europharm Limited*
- NetherlandsEnerzair Breezhaler 114 micrograms/46 micrograms/136 micrograms, inhalatiepoeder in harde capsuleNovartis Europharm Limited
- PolandEnerzair BreezhalerNovartis Europharm Limited
- CanadaENERZAIR BREEZHALERNOVARTIS PHARMACEUTICALS CANADA INC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/201654fd-5b1c-444e-9d46-5836e5784aa3 GET /v1/drugs/201654fd-5b1c-444e-9d46-5836e5784aa3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "indacaterolum 150 mcg + glycopyrronium 50 mcg + mometasoni-17 furoas 160 mcg",
"valid_from": "2021-01-01",
"limitations": "[{\"description\":\"Zur Erhaltungstherapie von Patienten mit schwerem Asthma, welche mit einer Erhaltungstherapie aus einem lang wirksamen Beta2-Agonisten und einem hochdosierten inhalativen Kortikosteroid nicht ausreichend eingestellt sind und eine oder mehr Exazerbationen in den letzten 12 Monaten erlitten haben<br>\\noder<br>\\nfür Patienten mit schwerem Asthma, welche bereits mit einer Kombination von LABA/LAMA und ICS mit mehreren Inhalatoren therapiert werden.<br>\\n<br>\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2021-01-01\",\"validTo\":null}]",
"galenic_form": "Inh Kaps 150/50/160mcg",
"therapeutic_area": null,
"sl_inclusion_date": "2021-01-01",
"self_retention_pct": 10
}See everything about indacaterol, glycopyrronium bromid und mometason.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.